Brought to you by 
Astellas and Ambit work on FLT3 kinase inhibitors; deal ending
14 Mar 2013
Executive Summary
Ambit Biosciences (cancer and inflammatory disease therapies) has announced that it will jointly develop its lead compound AC220 for acute myeloid leukemia, plus other FLT3 kinase inhibitors, with Japan's Astellas Pharma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas and Ambit work on FLT3 kinase inhibitors; deal ending
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice